Citius pharmaceuticals advances efforts to spin off oncology asset, i/ontak, into a standalone public company

Cranford, n.j. , march 30, 2023 /prnewswire/ -- citius pharmaceuticals, inc. ("citius" or the "company") (nasdaq: ctxr) , a late-stage biopharmaceutical company developing and commercializing first-in-class critical care products, today announced that maxim group llc will serve as financial advisor to its wholly-owned subsidiary, citius acquisition corp. inc., in connection with the intended formation of a separate publicly-traded entity to commercialize and grow citius' oncology asset, i/ontak.
CTXR Ratings Summary
CTXR Quant Ranking